Tuberculosis Vaccine Phase 2b Trial Launched

A coalition of groups announced yesterday the beginning of a Phase 2b trial of MVA85A, a new investigational vaccine for tuberculosis (TB). The groups behind the vaccine are Aeras, a US-based non-profit development organization, and the Oxford-Emergent Tuberculosis Consortium, which is a joint venture between the University of Oxford in the UK and Emergent BioSolutions, a US-based pharmaceutical company.

The trial will test MVA85A on approximately 1,400 adults aged 18-50 in Senegal and South Africa who are infected with HIV. MVA85A is designed to boost the response of T-cells. TB is a leading cause of death for people with HIV; people with HIV living in countries where TB is common are twenty times more likely to get TB than those who do not have HIV.

Source

New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in People Living with HIV in Senegal and South Africa [Press Release]